Does SILTUXIMAB Cause Neoplasm progression? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Neoplasm progression have been filed in association with SILTUXIMAB (Sylvant). This represents 2.8% of all adverse event reports for SILTUXIMAB.
13
Reports of Neoplasm progression with SILTUXIMAB
2.8%
of all SILTUXIMAB reports
12
Deaths
0
Hospitalizations
How Dangerous Is Neoplasm progression From SILTUXIMAB?
Of the 13 reports, 12 (92.3%) resulted in death.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SILTUXIMAB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does SILTUXIMAB Cause?
Off label use (96)
Drug ineffective (72)
Disease progression (32)
Immune effector cell-associated neurotoxicity syndrome (28)
Death (27)
Cytokine release syndrome (26)
Hypertension (24)
Product use in unapproved indication (24)
Drug effective for unapproved indication (23)
Cataract (19)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which SILTUXIMAB Alternatives Have Lower Neoplasm progression Risk?
SILTUXIMAB vs SILVER SULFADIAZINE
SILTUXIMAB vs SIMEPREVIR
SILTUXIMAB vs SIMPONI
SILTUXIMAB vs SIMVASTATIN
SILTUXIMAB vs SINGULAIR